The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial | Zendy

Andrew Grey | Zendy; Mark J Bolland | Zendy; Greg Gamble | Zendy; D. Wattie | Zendy; Anne Horne | Zendy; James S. Davidson | Zendy; Ian R. Reid | Zendy

Open Access

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial

Author(s) -

Andrew Grey,

Mark J Bolland,

Greg Gamble,

D. Wattie,

Anne Horne,

James S. Davidson,

Ian R. Reid

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-2646

Subject(s) - rosiglitazone , agonist , bone mineral , endocrinology , medicine , postmenopausal women , peroxisome proliferator activated receptor , receptor , chemistry , osteoporosis

Thiazolidinediones, which are peroxisome proliferator-activated receptor-gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor-gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research